MEPI-AVC - Evaluation of the efficacy and safety of mepivacaine on the neurological sequelae of cerabral infarction

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514481-39-00

Enrollment

Registered

2024-08-22

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Brief summary

he response is defined as an improvement 1h (+/- 30min) after injection, compared to the evaluation before mepivacaine injection, on at least one of the clinical scores specific to the symptoms: language, motor skills, visual skills

Interventions

DRUGCARBOCAINE 20 mg/ml

DRUGsolution injectable

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
he response is defined as an improvement 1h (+/- 30min) after injection, compared to the evaluation before mepivacaine injection, on at least one of the clinical scores specific to the symptoms: language, motor skills, visual skills	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026